Determination of dosimetric characteristics of a new design 125I brachytherapy source with marker of Ag+Al2O3 using the monte carlo code MCNPX

[1] D. Nori, Conformal brachytherapy of prostate cancer: an effective outpatient treatment. Cancer Watch 1 (1992), 124–126. [2] K.J. Russell and J.C. Blasko, Recent advances in interstitial brachytherapy for localized prostate cancer. Probl. Urol. 7 2 (1993), 260–278. [3] M.S. Porrazzo, B.S. Hilaris, C.R. Moorthy, A.E. Tchelebi, C.A. Mastoras, L.L. Shih, L. Stabile and N. Salvaras, Permanent interstitial implantation using palladium-103: The New York Medical college preliminary experience. Int. J. Rad. Onc. Biol. Phys. 23 (1992), 1033–1036. [4] J.C. Blasko, K. Wallner, P.D. Grimm and H. Ragde, Prostate specific antigen based control following ultrasound guided 125I implantation for Stage T1/T2 Prostate carcinoma. J. Urol. 154 (1995), 1096–1099. [5] Duggan DM, Improved radial dose function estimation using current version MCNP Mont-Carlo simulation: Model 6711 and ISC3500 125I brachytherapy sources, Appli Radiat Isot. 61 (2004),1443-1450. [6] Usgaonker SR, MCNP Modeling of prostate brachytherapy and of organ dosimetry, 2003; MSc thesis, USA. [7] U. J. Park, J. S Lee, K. J. Son, H. S. Han, S. S. Nam, The adsorption of 125I on a Ag+Al2O3 rod as a carrier body for a brachytherapy source. Journal of Radioanalytical and Nuclear Chemistry. 277 2 (2008), 429–432. [8] M.J. Rivard, B.M. Coursey, L.A. DeWerd, W.F. Hanson, M.S. Huq, G.S. Ibbott, M.G. Mitch, R. Nath and J.F. Williamson, Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations, Med. Phys. 31 (2004), 633–674. [9] R. Nath and N. Yue, Dosimetric characterization of a newly designed encapsulated interstitial brachytherapy source of iodine-125—model LS-1 BrachyseedTM, Appl. Radiat. Isot. 55 (2001), 813–821. [10] J.F. Briesmeister, Editor, MCNP-4C A General Monte Carlo N-Particle Transport Code System—Version 4C, Los Alamos National Laboratory, Louisiana (2000). [11] M. Sadeghi, G. Raisali, S.H. Hosseini and A. Shavar, Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA 103Pd brachytherapy source, Med. Phys. 34 (2008), 1288–1294. [12] Z. Li, J.R. Palta and J.J. Fan, Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source, Med. Phys. 27 (2000), pp. 1108–1112. [13] M.J. Rivard, A discredited approach to determining TG-43 brachytherapy dosimetry parameters: case study using Monte Carlo calculation for the 103Pd MED3633 source, Appl. Radiat. Isot. 55 (2001), 775–782. [14] Z. Li, J.R. Palta and J.J. Fan, Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source, Med. Phys. 27 (2000), 1108–1112. [15] A.S. Meigooni, Z. Bharucha, M. Yoe-Sein and K. Sowards, Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source, Med. Phys. 28 (2001), 2568–2575. [16] Ali S. Meigooni,a) Joshua L. Hayes, Hualin Zhang, and Keith Sowards, Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE™125I brachytherapy source, Med. Phys. 29 9 (2002), 2152–2158. [17] J. F. Williamson, H. Perera, and Z. Li, Comparison of calculated and measured hetrogeneity correction factors for 125I, 137Cs, and 192Ir brachytherapy source near localized hetrogeneities, Med. Phys. 20 (1993), 209–222. [18] A. S. Meigooni, M. M. Yoe-Sein, A. Al-Otoom, and K. Sowards, Determination of the dosimetric characteristics of interSource125 iodine brachytherapy source, Appl. Radiat. Isot. 56 (2002), 589–599. [19] A.S. Meigooni, D.G. Gearheart and K. Sowards, Experimental determination of dosimetric characteristics of Best® 125I brachytherapy source, Med. Phys. 27 9 (2000), 2168–2173. [20] R.E. Wallace and J.J. Fan, Report on the dosimetry of a new design 125I brachytherapy source. Med. Phys. 26 9 (1999), 1925–1931.